USFDA inspects Aurobindo Pharma's New Jersey-based facility, issues 10 observations

Aurobindo Pharma on November 9 reported an 85 percent year-on-year rise in consolidated net profit to Rs 757 crore for the July-September quarter of the current financial year.

The United States Food and Drug Administration (USFDA) issued 10 observations after conducting a pre-approval inspection at a facility linked to wholly-owned arm of Aurobindo Pharma in New Jersey, a regulatory filing stated on December 24.

The American drug regulator conducted the inspection at "new injectable facility of Eugia US Manufacturing LLC, situated at East Windsor, New Jersey, USA from December 11 to December 22, 2023," Aurobindo Pharma said, adding that "the inspection closed with 10 observations".

"The observations will be responded to within the stipulated time. The plant is yet to start commercial operations," the Indian pharma major further stated.

Also Read | Aurobindo subsidiary in Tirupati classified as VAI by US FDA

Aurobindo Pharma on November 9 reported an 85 percent year-on-year rise in consolidated net profit to Rs 757 crore for the July-September quarter of the current financial year.

Revenue came in at Rs 7,219.4 crore, up 25.7 percent from the year-ago quarter numbers of Rs 5,739.3 crore.

On December 22, shares of Aurobindo Pharma closed in the red, down almost 3 percent at Rs 1066.40 apiece.